Related Experiment Video

Updated: Aug 15, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

[Cardioprotective effects of anti-hypertensive medications]

Roland G Asmar1

  • 1Institut Cardiovasculaire, Paris, France. ra@icv.org

Current Medical Research and Opinion
|October 4, 2005
PubMed

Insights

The combination of perindopril and indapamide effectively reduces left ventricular hypertrophy and improves heart function in hypertensive patients, offering cardioprotective benefits beyond blood pressure control.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension research

Context:

  • Left ventricular hypertrophy (LVH) is a common complication of hypertension.
  • Different classes of antihypertensive medications show varying efficacy in regressing LVH.
  • Previous studies indicate ACE inhibitors, ARBs, and calcium antagonists are more effective than beta-blockers for LVH regression.

Purpose:

  • To evaluate the efficacy of a low-dose perindopril/indapamide combination versus enalapril monotherapy in reducing left ventricular mass.
  • To investigate the cardioprotective effects of perindopril/indapamide, independent of blood pressure reduction.
  • To explore the impact of perindopril/indapamide on coronary perfusion and cardiovascular events in hypertensive patients.

Summary:

  • The PICXEL study demonstrated that a perindopril/indapamide combination significantly reduced left ventricular mass compared to enalapril.
  • Perindopril/indapamide improved coronary perfusion in hypertensive patients with LVH, suggesting a direct cardioprotective mechanism.
  • Animal studies indicate the combination reverses hypertension-induced changes in arteriolar and capillary densities.

Impact:

  • Findings suggest perindopril/indapamide offers superior LVH regression and cardioprotection in hypertension.
  • The combination's benefits may extend to reducing cardiovascular events and improving microvascular function.
  • This research enhances understanding of how strategic antihypertensive choices mitigate cardiovascular complications.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...